NNZ-2591

NNZ-2591 is a synthetic peptide that has been studied for its potential therapeutic effects in treating various neurological disorders. It was developed by Neuren Pharmaceuticals, an Australian biopharmaceutical company.

History[edit | edit source]

Neuren Pharmaceuticals began the development of NNZ-2591 in the early 2000s. The peptide was initially synthesized as part of a research program aimed at discovering new treatments for neurological disorders.

Mechanism of Action[edit | edit source]

The exact mechanism of action of NNZ-2591 is not fully understood. However, it is believed to work by modulating the activity of certain neurons in the brain. This modulation may help to reduce the symptoms of neurological disorders.

Clinical Trials[edit | edit source]

As of 2021, NNZ-2591 has undergone several clinical trials. These trials have primarily focused on evaluating the safety and efficacy of the peptide in treating conditions such as Phelan-McDermid syndrome, Fragile X syndrome, and Pitt Hopkins syndrome.

Potential Applications[edit | edit source]

The potential applications of NNZ-2591 are vast. It has been studied for use in treating a variety of neurological disorders, including Autism Spectrum Disorder, Rett syndrome, and Traumatic Brain Injury.